公开(公告)号：AU2013251079B2

公开(公告)日：2017-03-23

申请号：AU2013251079

申请日：2013-04-19

Applicant: UCB PHARMA SA

Inventor： MICHEL ANNE ,  DOWNEY PATRICK ,  MONTEL FLORIAN ,  SCHELLER DIETER ,  CHRISTOPHE BERNARD

IPC: A61K31/395 ,  A61K31/4439 ,  A61K31/4523 ,  A61K31/4985 ,  A61P25/16

Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A

公开(公告)号：ES2627541T3

公开(公告)日：2017-07-28

申请号：ES13718320

申请日：2013-04-19

Applicant: UCB PHARMA SA

Inventor： MICHEL ANNE ,  DOWNEY PATRICK ,  MONTEL FLORIAN ,  SCHELLER DIETER ,  CHRISTOPHE BERNARD

IPC: A61K31/395 ,  A61K31/4439 ,  A61K31/4523 ,  A61K31/4985 ,  A61P25/16

Abstract: Una composición farmacéutica para uso en el tratamiento de la enfermedad de Parkinson (EP) en un mamífero, que comprende un primer agente farmacéutico y un segundo agente farmacéutico, en la que el primer agente farmacéutico es el antagonista de receptor de adenosina 2 (A2A) tozadenant y el segundo agente farmacéutico es el antagonista de receptor de D-aspartato de N-metilo (NMDA) de subtipo NR2B radiprodilo.

公开(公告)号：AU2013251079A1

公开(公告)日：2014-11-06

申请号：AU2013251079

申请日：2013-04-19

Applicant: UCB PHARMA SA

Inventor： MICHEL ANNE ,  DOWNEY PATRICK ,  MONTEL FLORIAN ,  SCHELLER DIETER ,  CHRISTOPHE BERNARD

IPC: A61K31/395 ,  A61K31/4439 ,  A61K31/4523 ,  A61K31/4985 ,  A61P25/16

Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A

公开(公告)号：CA2869216A1

公开(公告)日：2013-10-24

申请号：CA2869216

申请日：2013-04-19

Applicant: UCB PHARMA SA

Inventor： MICHEL ANNE ,  DOWNEY PATRICK ,  MONTEL FLORIAN ,  SCHELLER DIETER ,  CHRISTOPHE BERNARD

IPC: A61K31/395 ,  A61K31/4439 ,  A61K31/4523 ,  A61K31/4985 ,  A61P25/16

Abstract: The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A2A) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.